臨床泌尿器科66巻7号

2012年06月発行

綜説

筋層非浸潤性膀胱癌の治療戦略―膀胱内BCG注入療法および維持療法の有用性

著者： 宮崎淳¹ 西山博之¹

所属機関： ¹筑波大学医学医療系泌尿器科学

ページ範囲：P.453 - P.460

文献概要

要旨　筋層非浸潤性膀胱癌は，粘膜内にとどまるTa，粘膜下結合組織まで浸潤するT1，あるいは上皮内癌Tis（carcinoma in situ：CIS）として分類される。基本的に，経尿道的膀胱腫瘍切除（TURBT）および抗癌剤やBCGの膀胱内注入療法を中心とした膀胱温存治療の対象となる。一般に生命予後は良好であるが，高い頻度で膀胱内再発を繰り返すことから，治療後の異所性の再発や進行に留意して経過を観察しなければならない。このため，膀胱癌の診断，治療において，再発や進行に関するリスクの認識とそれに応じた治療の選択は極めて重要である。

参考文献

1）van Rhijn BW, Burger M, Lotan Y, et al：Recurrence and progression of disease in non-muscle-invasive bladder cancer：from epidemiology to treatment strategy. Eur Urol 56：430, 2009

2）Epstein JI, Amin MB, Reuter VR, et al：The World Health Organization/International Society of Urological Pathology consensus classification of urothelial（transitional cell）neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22：1435, 1998

3）Lopez-Beltran A and Montironi R：Non-invasive urothelial neoplasms：according to the most recent WHO classification. Eur Urol 46：170, 2004

4）MacLennan GT, Kirkali Z and Cheng L：Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51：889, 2007

5）Pan CC, Chang YH, Chen KK, et al：Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder：a clinicopathologic study of 1,515 cases. Am J Clin Pathol 133：788

6）日本泌尿器科学会・日本病理学会・日本医学放射線学会編：腎盂・尿管・膀胱癌取り扱い規約，第1版．金原出版，東京，2011

7）Babjuk M, Oosterlinck W, Sylvester R, et al：EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54：303, 2008

8）Babjuk M, Oosterlinck W, Sylvester R, et al：EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59：997, 2011

9）Witjes JA, Redorta JP, Jacqmin D, et al：Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer：review of the evidence and recommendations. Eur Urol 57：607

10）Kausch I, Sommerauer M, Montorsi F, et al：Photodynamic diagnosis in non-muscle-invasive bladder cancer：a systematic review and cumulative analysis of prospective studies. Eur Urol 57：595-606, 2010

11）Schumacher MC, Holmang S, Davidsson T, et al：Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light：results of a prospective, randomised, multicentre study. Eur Urol 57：293, 2010

12）Stenzl A, Penkoff H, Dajc-Sommerer E, et al：Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy：a multicenter randomized, double-blind, placebo-controlled trial. Cancer 117：938, 2011

13）Saito S：Transurethral en bloc resection of bladder tumors. J Urol 166：2148, 2001

14）Miladi M, Peyromaure M, Zerbib M, et al：The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 43：241, 2003

15）Jakse G, Algaba F, Malmstrom PU, et al：A second-look TUR in T1 transitional cell carcinoma：why? Eur Urol 45：539, 2004

16）Grimm MO, Steinhoff C, Simon X, et al：Effect of routine repeat transurethral resection for superficial bladder cancer：a long-term observational study. J Urol 170：433, 2003

17）Brauers A, Buettner R and Jakse G：Second resection and prognosis of primary high risk superficial bladder cancer：is cystectomy often too early? J Urol 165：808, 2001

18）Hinotsu S, Akaza H, Ohashi Y, et al：Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection：a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86：1818, 1999

19）Sylvester RJ, Oosterlinck W and van der Meijden AP：A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer：a meta-analysis of published results of randomized clinical trials. J Urol 171：2186, 2004

20）Pawinski A, Sylvester R and Kurth KH, et al：A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156：1934, 1996

21）Akaza H, Hinotsu S, Aso Y, et al：Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder：four-year results. The Bladder Cancer BCG Study Group. Cancer 75：552, 1995

22）Akaza H, Koiso K, Ozono S, et al：A clinical study of PMCJ-9（Bacillus Calmette-Guerin Connaught strain）treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol 33：382, 2003

23）Lamm DL, Blumenstein BA, Crawford ED, et al：A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325：1205, 1991

24）Shelley MD, Wilt TJ, Court J, et al：Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer：a meta-analysis of randomized trials. BJU Int 93：485, 2004

25）Bohle A, Jocham D, Bock PR：Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer：a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169：90, 2003

：a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 56：260, 2009

27）Malmstrom PU, Sylvester RJ, Crawford DE, et al：An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56：247, 2009

of the bladder. Urology 66：90, 2005

29）Herr HW and Dalbagni G：Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169：1706, 2003

30）Solsona E, Iborra I, Dumont R, et al：The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164：685, 2000

31）Lerner SP, Tangen CM, Sucharew H, et al：Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27：155, 2009

transitional cell carcinoma of the bladder：a randomized Southwest Oncology Group Study. J Urol 163：1124, 2000

33）Lamm DL：Preventing progression and improving survival with BCG maintenance. Eur Urol 37（Suppl 1：9）, 2000

34）Sylvester RJ, van der MA and Lamm DL：Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer：a meta-analysis of the published results of randomized clinical trials. J Urol 168：1964, 2002

35）Saint F, Irani J, Patard JJ, et al：Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 57：883, 2001

36）Colombel M, Saint F, Chopin D, et al：The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer：results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176：935, 2006

37）Hinotsu S, Akaza H, Naito S, et al：Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 108：187, 2011